BeOne Medicines price target raised by Morgan Stanley due to optimistic drug approval timeline.

From Yahoo Finance: 2025-06-28 08:35:00

Morgan Stanley raised BeOne Medicines (ONC) price target to $330 from $313, maintains an Overweight rating. Management aims for Sonrotoclax approval in 2026 and BGB16673 in 2027, analyst says Street estimates are too conservative. Source: TheFly.



Read more at Yahoo Finance: BeOne Medicines price target raised to $330 from $313 at Morgan Stanley